ReviewTransplant infectious disease : an official journal of the Transplantation Society
Molecular Respiratory Pathogen Panels in Lung Transplantation.
Review in Transplant infectious disease : an official journal of the Transplantation Society. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Donor-derived viral infections: the usual suspects and the new kids on the block.Transplant international : official journal of the European Society for Organ Transplantation · 2026Review
- Molecular Respiratory Pathogen Panels in Lung Transplantation.Transplant infectious disease : an official journal of the Transplantation SocietyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Molecular respiratory pathogen panels are an innovative tool for the rapid detection of respiratory pathogens and antimicrobial resistance genes, offering the potential to improve diagnostic accuracy and guide timely antimicrobial therapy. In lung transplantation, their application is especially appealing due to the high incidence of respiratory tract infections and the frequent involvement of multidrug-resistant organisms. This review summarizes the published experiences with molecular respiratory pathogen panels in lung transplant recipients. Current evidence has shown that these panels deliver results faster than conventional microbiology and can support clinical decision-making by confirming or excluding infections. Importantly, these tools cannot replace traditional diagnostics, which remain essential for pathogen susceptibility profiling and identifying organisms not included in the panels. An emerging application involves modulating perioperative antibiotic prophylaxis, where molecular panels may allow earlier adjustment of regimens to address potential donor-derived pathogens. Implemented within structured workflows, molecular panels could help reduce unnecessary antimicrobial exposure and the associated ecological impact. However, limitations still exist, including their inability to detect fungi or less common bacterial pathogens and the risk of over-interpreting colonizing flora. Defined protocols and diagnostic stewardship principles should therefore guide the integration of molecular panels into transplant practice. Further studies are needed to evaluate their cost-effectiveness and to identify patient subgroups who may benefit most from their use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.